Back to Authors

Stephens, Laura

0000-0002-9101-9326

Mayo Clinic

Department of Pathology, University of California San Diego, San Diego, California, USA.

Citations 12

Crizanlizumab and sickle cell disease: When should medications have their approval status revoked?
Jacobs, Jeremy W. , Stephens, Laura D. , Chooljian, David M. , Sharma, Deva , Adkins, Brian D. , Booth, Garrett S. , Jacobs, Jeremy W , Booth, Garrett , Adkins, Brian David , Stephens, Laura

American Journal of Hematology | February 27, 2024 | Volume: 99 | Issue: 6 | Pages: 1016-1018

10.1002/ajh.27275 Get It

Thrombosis risk with haemoglobin C trait and haemoglobin C disease: A systematic review
Jacobs, Jeremy W. , Sharma, Deva , Stephens, Laura D. , Rinder, Henry M. , Wheeler, Allison P. , Gerberi, Dana , Goel, Ruchika , Tormey, Christopher A. , Booth, Garrett S. , Bloch, Evan M. , Adkins, Brian D. , Rinder, Henry M , Wheeler, Allison P , Goel, Ruchika , Tormey, Christopher A , Booth, Garrett , Bloch, Evan M , Adkins, Brian David , Jacobs, Jeremy W , Stephens, Laura , Villalba, Cristina A. Figueroa , Woo, Jennifer S.

British Journal of Haematology | January 31, 2024 | Volume: 204 | Issue: 4 | Pages: 1500-1506

10.1111/bjh.19313 Get It

SummaryThe thrombotic risk with haemoglobin C trait (HbAC) or haemoglobin C disease (HbCC) is unclear. However, individuals with HbCC have demonstrated chronic haemolysis, higher blood viscosity and altered rheology when compared to individuals with wild‐type haemoglobin (HbAA). These physiological alterations may theoretically translate to increased risk of thrombosis; therefore, a systematic literature review was performed to investigate the possible association between HbAC and/or HbCC and thrombosis. Twenty‐two studies met inclusion criteria representing 782 individuals with HbAC (n = 694) or HbCC (n = 88). Fifteen studies described the presence/absence of venous thromboembolism (VTE) in patients with HbAC (n = 685) or HbCC (n = 79), while seven studies described patients with HbAC (n = 9) or HbCC (n = 9) and arterial thrombosis. Most (n = 20) studies were case reports or case series; however, two studies suggested a potential increased VTE risk with HbAC compared to HbAA in (i) all patients (OR 2.2, 95% CI: 0.9–5.5) and in (ii) pregnant individuals (RR 3.7, 95% CI 0.9–16). This review is the largest assessment of patients with HbC trait or disease and thrombosis to date; despite its limitations, the findings suggest HbC may be a predisposing risk factor to thrombosis. Prospective cohort studies are warranted to definitively elucidate the risk of thrombosis in this population.